Myriad Genetics Q2 revenue $179.3M (+7% ex-divestitures); GAAP EPS -$0.18; cuts FY EPS guidance

MYRIAD GENETICS INC

2022-Q2 EPS reported -$0.43 revenue$344,200,000

GAAP diluted EPS of $(0.18); adjusted EPS $0.04, down from $0.12 YoY.
GeneSight volumes up 39% YoY; hereditary cancer volumes down 4% YoY but stabilizing.
FY2022 revenue guidance unchanged at $670-$700M; adjusted EPS cut to $(0.10)-$0.00 from $0.00-$0.20.
Cash $283.6M; paid $48M qui tam settlement in Q2; no debt.
Launched Precise Oncology Solutions; liquid biopsy test via Illumina/Intermountain expected in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.